Lead Product(s): KAN-101
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2020
Anokion plans to initiate its multi-center Phase 1 study for KAN-101 in people with celiac disease in the first quarter of 2020.